NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Kailera Therapeutics

Kailera Therapeutics

Public
Waltham, MassachusettsBiotechhttps://www.kailera.com/

Kailera Therapeutics is now publicly traded

The data on this page reflects Kailera Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Apr 17, 2026

Last Round

Series B

Oct 14, 2025

Total Funding Raised

$1.72B

Company Overview

Kailera Therapeutics is a biopharmaceutical company that develops a diversified pipeline of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions.

Sector

Biotech

Verticals

Life Sciences, LOHAS & Wellness

AI Layer

Non-AI

Keywords

obesity treatmentweight loss drugGLP-1GIPbiopharmaceuticalmetabolic diseaseclinical-stage biotechoral weight lossinjectable therapydrug developmentmetabolic healthbiotech IPO

Kailera Therapeutics Comparables

Compare Kailera Therapeutics with similar companies based on industry and business-model similarity.

Kailera Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Viking Therapeutics, Inc.
92%
Structure Therapeutics
87%
Pfizer
84%

Kailera Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOApr 17, 2026
Series BOct 14, 2025
Series AOct 1, 2024

Key People

Founding team and executive leadership

Daniela Vincent

Administrative Manager, Office Of The CEO

Executive Team

Ron Renaud

President CEO

Executive Team

Doug Bakan

Chief Technology Officer

Executive Team

Paul Burgess

Chief Operating Officer And Chief Business Officer

Executive Team

Kailera Therapeutics Investors

Notable investors and investment history

Kailera Therapeutics investors
InvestorRounds
Sirona CapitalSeries B
JefferiesIPO
Surveyor CapitalSeries B
CPP InvestmentsSeries B
Evercore ISIIPO
Bain Capital Life SciencesSeries B, Series A
Janus Henderson GroupSeries B

Kailera Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kailera Therapeutics Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range171
Year Founded2024
Last FundingOct 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.